Estrogen replacement therapy after coronary angioplasty in women.
Estrogen replacement therapy after coronary angioplasty in women.
复制标题
女性冠状动脉血管成形术后的雌激素替代治疗。
DOI：
10.1016/s0735-1097(96)00443-3
复制
发表时间：
1997
影响因子：
24
通讯作者：
B. Mccallister
中科院分区：
文献类型：
--
作者：
James H. O'Keefe;Susie C Kim;Ralph R Hall;Vicki C Cochran;Stephanie L Lawhorn;B. Mccallister
目标。本研究的目的是评估雌激素替代治疗对绝经后妇女首次经皮冠状动脉腔内成形术(PTCA)后再狭窄、心肌梗死、中风和死亡等远期结局的影响。观察性和流行病学研究、基础实验室研究和临床试验一致表明，雌激素替代疗法与对女性有益的心血管效应有关。这些心脏保护作用可能与患有冠状动脉疾病的女性特别相关，比如那些接受过经皮冠状动脉腔内成形术的女性。这是一项回顾性研究，包括1982至1994年间接受择期PTCA的337名女性。治疗组包括137名连续接受长期雌激素治疗的妇女，她们在择期PTCA时和在随访期间接受雌激素治疗。对照组包括200名与雌激素组电脑匹配的女性。平均随访时间(65±35)个月。雌激素组的精算存活率更高，7年存活率为93%，而对照组为75%(p=0.001)。7年后，雌激素组的心血管事件(死亡、非致命性心肌梗死或非致命性中风)的发生率显著降低(12%比对照组的35%，p=0.001)。在两组患者中，在随后的随访中需要进行血运重建的情况相似。多变量分析发现，糖尿病、雌激素治疗(调整后的风险比0.38，95%可信区间0.19至0.79)和左心室射血分数(40%)是心血管死亡或心肌梗死的独立相关因素。雌激素替代疗法与绝经后妇女PTCA术后长期结果的改善有关(J am Coll心脏ol 1997；29：1-5)
Objectives. The purpose of this study was to assess the effects of estrogen replacement therapy on long-term outcome, including restenosis, myocardial infarction, stroke and death after a first percutaneous transluminal coronary angioplasty (PTCA) procedure, in postmenopausal women.Background. Observational and epidemiologic studies, basic laboratory research and clinical trials consistently suggest that estrogen replacement therapy is associated with beneficial cardiovascular effects in women. These cardioprotective actions may be particularly relevant to women with coronary artery disease, such as those who have undergone PTCA.Methods. This was a retrospective study that included 337 women who underwent elective PTCA between 1982 and 1994. The treatment group consisted of 137 consecutive women receiving long-term estrogen therapy at the time of elective PTCA and during follow-up. The control group comprised 200 women who were computer-matched with the estrogen group. The mean follow-up period was 65 ± 35 months.Results. Actuarial survival was superior in the estrogen group; the 7-year survival rate was 93% for the estrogen group versus 75% for the control group (p = 0.001). The cardiovascular event rate (death, nonfatal myocardial infarction or nonfatal stroke) was significantly lower in the estrogen group at 7 years (12% vs. 35% in the control group, p = 0.001). The need for subsequent revascularization during follow-up was similar in the two groups. Multivariable analysis identified diabetes, estrogen therapy (adjusted risk ratio 0.38, 95% confidence interval 0.19 to 0.79) and left ventricular ejection fraction <40% as independent correlates of cardiovascular death or myocardial infarction during follow-up.Conclusions. Estrogen replacement therapy was associated with an improved long-term outcome after PTCA in postmenopausal women.(J Am Coll Cardiol 1997;29:1–5)>
登录
查看更多内容
DOI：
10.1097/00006254-199202000-00027
发表时间：
1991-09
期刊：
The New England journal of medicine
影响因子：
--
作者：
M. Stampfer;G. Colditz;W. Willett;J. Manson;B. Rosner;F. Speizer;C. Hennekens
通讯作者：
M. Stampfer;G. Colditz;W. Willett;J. Manson;B. Rosner;F. Speizer;C. Hennekens
影响因子：
158.5
作者：
Grodstein, F;Stampfer, MJ;Hennekens, CH
通讯作者：
Hennekens, CH
影响因子：
37.8
作者：
KELSEY, SF;JAMES, M;DETRE, KM
通讯作者：
DETRE, KM
雌激素和孕激素与绝经后妇女心血管疾病关系的综述。
影响因子：
--
作者：
Psaty,BM;Heckbert,SR;Atkins,D;Siscovick,DS;Koepsell,TD;Wahl,PW;LongstrethJr,WT;Weiss,NS;Wagner,EH;Prentice,R
通讯作者：
Prentice,R